Medical and Pharmaceutical Medical cannabis cuts daily opioid-use in chronic pain patients: study The study adds to a body of emerging research suggesting pot is effective in reducing opioid use Natalia Buendia CalvilloJanuary 31, 2022
Cannabis Young adults who use cannabis have better sex: study Substances helped lower people's anxiety and shame, but also lead to riskier sexual behaviours Natalia Buendia CalvilloJanuary 26, 2022
International Australian researchers granted $3M for psychedelic mental health treatments Two separate trials will look at MDMA for alcohol use and PTSD, as well as psilocybin-assisted therapy for anorexia nervosa Nick LabaJanuary 17, 2022
Driving THC-related driving injuries doubled since legalization: UBC study The largest increase in drivers with moderate injuries was seen in men over 50 Natalia Buendia CalvilloJanuary 14, 2022
Driving Brain imaging shows potential for cannabis impairment test A recent study suggests the method could be used in roadside assessments of impaired driving from THC Kathryn TindaleJanuary 12, 2022
Science and Research More studies are showing how cannabinoids help fight Covid Certain cannabinoids appear to block the virus from attaching to the 'doorway' of the cell Natalia Buendia CalvilloJanuary 12, 2022
Canada ATMA to run clinical trial for synthetic psilocybin on medical professionals Following the trial's approval from Health Canada, psychedelic practitioners can now apply to be research subjects Natalia Buendia CalvilloJanuary 11, 2022
Canada Study warning of post-legalization pot poisonings doesn’t control for illicit products The research shows a sharp uptick in young children going to hospital, in the period after legal edibles came to market Natalia Buendia CalvilloJanuary 7, 2022
Psychedelics Palliative care providers see psychedelic-assisted therapy as treatment option for existential distress: study Currently treatments are largely insufficient, so care providers encourage more research despite stigma Natalia Buendia CalvilloDecember 30, 2021
Business Pfizer buys firm with cannabinoid therapy in clinical trial Olorinab is a CB2 receptor agonist in a Phase 2 trial for IBS Nick LabaDecember 15, 2021